3-methoxytyramine has been researched along with Gelineau Syndrome in 1 studies
3-methoxytyramine: RN given refers to parent cpd
3-methoxytyramine : A monomethoxybenzene that is dopamine in which the hydroxy group at position 3 is replaced by a methoxy group. It is a metabolite of the neurotransmitter dopamine and considered a potential biomarker of pheochromocytomas and paragangliomas.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bowersox, SS | 1 |
| Kilduff, TS | 1 |
| Faull, KF | 1 |
| Zeller-DeAmicis, L | 1 |
| Dement, WC | 1 |
| Ciaranello, RD | 1 |
1 other study available for 3-methoxytyramine and Gelineau Syndrome
| Article | Year |
|---|---|
Brain dopamine receptor levels elevated in canine narcolepsy.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amygdala; Animals; Brain Chemistry; Caudate Nucleus; Dogs; Dopamine; | 1987 |